Clinical aspects of antimicrobial resistance

Mayo Clinic Proceedings

Volumn 75, Issue 2, 2000, Pages 200-214

  Virk, Abinash ^a   Steckelberg, James M ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; METICILLIN; PENICILLIN G; PENICILLINASE; SULBACTAM; TAZOBACTAM; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; COMMUNICABLE DISEASE; CONFERENCE PAPER; DRUG MECHANISM; HOSPITAL INFECTION; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRESCRIPTION;

EID: 0033953344     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.2.200     Document Type: Conference Paper

References (134)

1. Cohen ML. Epidemiology of drug resistance: implications for a postantimicrobial era. Science 1992;257:1050-1055
2. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 1997;24(Suppl 1):S17-S18
3. Report of the ASM task force on antibiotic resistance. Antimicrob Agents Chemother Suppl 1995; 1-23
4. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y (Laboratory Investigator Group). Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997:29:249-257
5. American Society of Microbiology, Public Scientific Affairs Board. Report of the ASM Task Force on Antibiotic Resistance. Washington, DC: American Society of Microbiology; 1995
6. Cetron MS, Jernigan DB, Breiman RF (DRSP Working Group). Action plan for drug-resistant Streptococcus pneumoniae [editorial]. Emerg Infect Dis 1995;l:64-65
7. 1996 ASCP Susceptibility Testing Group, American Society of Clinical Pathologists. United States geographic bacteria susceptibility patterns. Am J Clin Pathol 1998;109:144-152
8. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-1673
9. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-523
10. Segal-Maurer S, Urban C, Rahal JJ Jr. Current perspectives on multidrug-resistant bacteria: epidemiology and control. Infect Dis Clin North Am 1996 Dec;10:939-957
11. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998;26:1188-1195
12. Chen DK, McGeer A, de Azavedo JC, Low DE (Canadian Bacterial Surveillance Network). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999'341'233-239
13. Pikis A, Donkersloot JA, Akram S, Keith JM, Campos JM, Rodriguez WJ. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae [published erratum appears in J Antimicrob Chemother 1997;40:462]. J Antimicrob Chemother 1997;40:105-108
14. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1835
15. Eliopoulos GM. Vancomycin-resistant enterococci: mechanism and clinical relevance. Infect Dis Clin North Am 1997 Dec;ll:851-865
16. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci: epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997 Dec;ll:813849
17. Gerberding JL, McGowan JE Jr, Tenover FC. Emerging nosocomial infections and antimicrobial resistance. Curr Clin Top Infect Dis 1999;19:83-98
18. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998:279:593-598
19. Collignon P, Gosbell l, Vickery A, Nimmo G, Stylianopoulos T, Gottlieb T (Australian Group on Antimicrobial Resistance). Community-acquired meticillin-resistant Staphylococcus aureus in Australia [letter]. Lancet 1998;352:145-146
20. Scheel O, Lyon DJ, Rosdahl VT. Adeyemi-Doro FA, Ling TK, Cheng AF. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993 [published erratum appears in J Antimicrob Chemother 1996;38:919]. J Antimicrob Chemother 1996;37:243-251
21. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997;24(Suppl 1):S67-S73
22. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997 [published erratum appears in MMWR Morb Mortal Wkly Rep 1997;46:851]. MMWR Morb Mortal Wkly Rep 1997;46:765-766
23. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997 [published erratum appears in MMWR Morb Mortal Wkly Rep 1997;46:851]. MMWR Morb Mortal Wkly Rep 1997; 46:813-815
24. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis 1998:26:1182-1187
25. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998;27(Suppl 1):S75-S83
26. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998:26:1196-1199
27. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993:42:597-599
28. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 1998:4:239-249
29. Nordmann P. Trends in -lactamase resistance among Enterobacteriaceae. Clin Infect Dis 1998;27(Suppl 1):S100-S106
30. Lind I. Antimicrobial resistance in Neisseria gonorrhoeae. Clin Infect Dis 1997;24(Suppl 1):S93-S97
31. Gordon SM, Carlyn CJ, Doyle U, Knapp CC, Longworth DL, Hall GS, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors. Ann Intern Med 1996:125:465-470
32. Drusano GL. Infection in the intensive care unit: -lactamasemediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis 1998;27(Suppl 1):S111-S116
33. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997:103:51-59
34. Bush K. Metallo-lactamases: a class apart. Clin Infect Dis 1998; 27(Suppl 1):S48-S53
35. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in anaerobes. Clin Infect Dis 1997;24(Suppl 1):S110-S120
36. MacGowan AP, Bowker KE, Bennett PM, Lovering AM. Surveillance of antimicrobial resistance [letter]. Lancet 1998:352:1783
37. Denning DW. Can we prevent azole resistance in fungi? Lancet 1995:346:454-455
38. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;31: 327-332
39. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP (SCOPE Participant Group). National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;30:121129
40. Sterling TR, Gasser RA Jr, Ziegler A. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin Infect Dis 1996:23:187-188
41. Denning DW, Baily GG, Hood SV. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 1997;16:261-280
42. Levy SB, FitzGerald GB, Macone AB. Changes in intestinal flora of farm personnel after introduction of tetracycline-supplemented feed on a farm. N Engl J Med 1976;295:583-588
43. McGowan J. Antimicrobial resistance on hospital organisms and its relation to antibiotics use. Rev Infect Dis 1983:5:1033-1048
44. Baquero F, Martinez-Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991;28(Suppl C):31-38
45. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, VauzelleKervroedan F, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-370
46. Cartledge JD, Midgley J, Gazzard BG. Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study. Genitourinary Med 1997;73:471-474
47. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Watdner A, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994;8:945-950
48. Dronda F, Alonso-Sanz M, Laguna F, Chaves F, Martinez-Suarez JV, Rodriguez-Tudela JL, et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996;15:446-452
49. Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 1996;10:263-268
50. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127-1133
51. Dever LL, China C, Eng RH, O'Donovan C, Johanson WG Jr. Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Center: association with antibiotic usage. Am J Infect Control 1998:26:40-46
52. Gaynes R. Antibiotic resistance in ICUs: a multifaceted problem requiring a multifaceted solution [editorial]. Infect Control Hosp Epidemiol 1995:16:328-330
53. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998;27(Suppl 1):S117S124
54. Manian FA, Meyer L, Jenne J, Owen A, Taff T. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol 1996:17:222-226
55. Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 1997 Dec;ll:875-888
56. Pfaller MA, Messer SA, Houston A, Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National Epidemiology of Mycoses Survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998:31:289-296
57. Toltzis P, Hoyen C, Spinner-Block S, Salvator AE, Rice LB. Factors that predict preexisting colonization with antibiotic-resistant gramnegative bacilli in patients admitted to a pédiatrie intensive care unit. Pediatrics 1999:103:719-723
58. Verwaest C, Verhaegen J, Ferdinande P, Schetz M, Van den Berghe G, Verbist L, et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med 1997:25:6371
59. Sproat U, InglisTJ. A multicentre survey of hand hygiene practice in intensive care units. J Hosp Infect 1994:26:137-148
60. Faryna A, Wergowske GL, Goldenberg K. Impact of therapeutic guidelines on antibiotic use by residents in primary care clinics. J Gen Intern Med 1987:2:102-107
61. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-904
62. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis [published erratum appears in JAMA 1998:279:1702]. JAMA 1998:279:875-877
63. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States [published erratum appears in JAMA 1998:279:434]. JAMA 1995:273:214219
64. Kunin CM. Resistance to antimicrobial drugs-a worldwide calamity. Ann Intern Med 1993:118:557-561
65. Tauxe RV, Puhr NO, Wells JG, Hargrett-Bean N, Blake PA. Antimicrobial resistance of Shigella isolates in the USA: the importance of international travelers. J Infect Dis 1990:162:1107-1111
66. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999:340:1525-1532
67. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, CanuetoQuintero J, Sanchez-Porto A, Vergara-Campos A, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997;24:1052-1059
68. Doone JL, Klespies SL, Sabella C. Risk factors for penicillin-resistant systemic pneumococcal infections in children. Clin Pediatr 1997:36:187-191
69. Hofmann J, Cetron MS, Parley MM, Baughman WS, Facklam RR, Elliott JA, et al. The prevalence of drug-resistant Streptococcus pneumonias in Atlanta. N Engl J Med 1995;333:481-486
70. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-1153
71. Khachatourians GG. Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. CMAJ 1998;159:1129-1136
72. Marwick C. Animal feed antibiotic use raises drug resistance fear. JAMA 1999:282:120-122
73. Riley LW, Cohen ML, Seals JE, Blaser MJ, Birkness KA, Hargrett NT, et al. Importance of host factors in human salmonellosis caused by multiresistant strains of Salmonella. J Infect Dis 1984; 149:878-883
74. MacDonald KL, Cohen ML, Hargrett-Bean NT, Wells JG, Fuhr ND, Collin SF, et al. Changes in antimicrobial resistance of Salmonella isolated from humans in the United States. JAMA 1987;258:14961499
75. Griggs DJ, Hall MC, Jin YF, Piddock U. Quinolone resistance in veterinary isolates of Salmonella. J Antimicrob Chemother 1994; 33:1173-1189
76. Gaunt PN, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996:37:747-757
77. Threlfall EJ, Graham A, CheastyT, Ward LR, RoweB. Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996. J Clin Pathol 1997:50:1027-1028
78. Threlfall EJ, Frost JA, Rowe B. Fluoroquinolone resistance in Salmonellas and Campylobacters from humans [letter]. BMJ 1999; 318:943-944
79. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102:284-293
80. Mayer KH, Opal SM, Medeiros AA. Mechanisms of antibiotic resistance. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995. pp 212225
81. Neu HC. The crisis of antibiotic resistance. Science 1992:257: 1064-1073
82. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-1132
83. Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, et al. Ceftazidime-resistant Klebsiella pneumonias and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996;174:529-536
84. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enteroöacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-590
85. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-670
86. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998:158:522-527
87. Harbarth S, Rutschmann 0, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998;158:182-189
88. Arditi M, Mason EO Jr, Bradley JS, Tan TQ, Barson WJ, Schütze GE, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998:102:1087-1097
89. Tan TQ, Mason EO Jr, Barson WJ, Wald ER, Schütze GE, Bradley JS, et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillinnonsusceptible Streptococcus pneumoniae. Pediatrics 1998:102: 1369-1375
90. Coudron PE, Moland ES, Sanders CC. Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol 1997;35:2593-2597
91. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44(RR-12):1-13
92. Rahman M. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 1998:41:325-328
93. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998;41:11-18
94. Murray BE. Diversity among multidrug-resistant enterococci. Emerg Infect Dis 1998;4:37-47
95. Antony SJ, Ladner J, Stratton CW, Raudales F, Dummer SJ. Highlevel aminoglycoside-resistant enterococcus causing endocarditis successfully treated with a combination of ampicillin, imipenem and vancomycin. Scand J Infect Dis 1997;29:628-630
96. Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wallactive agents. J Infect Dis 1996;173:909-913
97. Lorian V, Fernandes F. Synergic activity of vancomycin-quinupristin/ dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother 1997;39:63-66
98. Kang SL, Rybak MJ. In-vitro bactericidal activity of quinupristin/ dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997;39(Suppl A):33-39
99. Hill RL, Smith CT, Seyed-Akhavani M, Casewell MW. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium. J Antimicrob Chemother 1997;39:23-28
100. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145-151
101. Noskin GA. Vancomycin-resistant enterococci: clinical, microbiologie, and epidemiologic features. J Lab Clin Med 1997;130:14-20
102. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721724
103. Patel R, Rouse MS, Piper KE, Cockerill FR III, Steckelberg JM. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998:30:89-92
104. Centers for Disease Control and Prevention. Defining the public health impact of the drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep 1996;45(RR1):1-21
105. Hardie WD, Roberts NE, Reising SF, Christie CD. Complicated parapneumonic effusions in children caused by penicillinnonsusceptible Streptococcus pneumoniae. Pediatrics 1998;101:388-392
106. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain [published erratum appears in N Engl J Med 1995:333:1655]. N Engl J Med 1995:333:474-480
107. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am 1997 Dec;ll:867-874
108. Friedland IR, Klugman KP. Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high-dosage cefotaxime. Antimicrob Agents Chemother 1997:41:1888-1891
109. Schreiber JR, Jacobs MR. Antibiotic-resistant pneumococci. Pediatr Clin North Am 1995 Jun;42:519-537
110. John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994:18:188-193
111. Doit C, Barre J, Cohen R, Bonacorsi S, Bourrillon A, Bingen EH. Bactericidal activity against intermediately cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with bacterial meningitis treated with high doses of cefotaxime and vancomycin. Antimicrob Agents Chemother 1997:41:2050-2052
112. Viladrich PF, Gudiol F, Linares J, Pallares R, Sabate I, Rufi G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991;35:2467-2472
113. Klugman KP, Madhi SA. Emergence of drug resistance: impact on bacterial meningitis. Infect Dis Clin North Am 1999 Sep;13:637-646
114. Paris MM, Hickey SM, Uscher Ml, Shelton S, Olsen KD, McCracken
115. GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38:1320-1324
116. Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH Jr. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993;37:1630-1636
117. Tunkel AR, Scheid WM. Issues in the management of bacterial meningitis. Am Fam Physician 1997;56:1355-1362
118. Fitoussi F, Doit C, Benali K, Bonacorsi S, Geslin P, Bingen E. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother 1998;42:942-944
119. Asensi F, Otero MC, Perez-Tamarit D, Rodrlguez-Escribano I, Cabedo JL, Gresa S, et al. Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus. J Chemother 1993;5:133-134
120. Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A (Meropenem Meningitis Study Group). A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995;36:85-97
121. Wang WC, Wong WY, Rogers ZR, Wilimas JA, Buchanan GR, Powars DR. Antibiotic-resistant pneumococcal infection in children with sickle cell disease in the United States. J Pediatr Hematol Oncol 1996:18:140-144
122. Carratala J, Marron A, Fernandez-Sevilla A, Linares J, Gudiol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1997;24:148-152
123. Pfaller MA, Jones RN. Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagn Microbiol Infect Dis 1997;29:199-201
124. Klugman KP, Gootz TD. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997; 39:51-55
125. Nuorti JP, Butler JC, Crutcher JM, Guevara R, Welch D, Holder P, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998:338:1861-1868
126. Espinel-lngroff A. Clinical relevance of antifungal resistance. Infect Dis Clin North Am 1997 Dec;ll:929-944
127. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al (Candidemia Study Group and the National Institute). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994:331:1325-1330
128. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997:25:584-599
129. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al (Finnish Study Group for Antimicrobial Resistance). The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997:337:441-446
130. King JW, White MC, Todd JR, Conrad SA. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992:14:908-915
131. Young EJ, Sewell CM, Koza MA, Clarridge JE. Antibiotic resistance patterns during aminoglycoside restriction. Am J Med Sci 1985:290:223-227
132. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 1996;313:387-391
133. Nowak R. Hungary sees an improvement in penicillin resistance. Science 1994;264:364
134. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997:46:626-628: 635